Columbus Circle Capital Corp II Unit (CMIIU) is a specialized acquisition company targeting opportunities within the life sciences sector, specifically in innovative biotechnology, pharmaceuticals, and healthcare firms poised for significant growth through strategic mergers and acquisitions. Leveraging a seasoned management team with profound industry expertise, CMIIU is strategically positioned to harness emerging healthcare trends and advancements in therapeutics and diagnostics. The company aims to identify and partner with transformative enterprises, reinforcing its commitment to sustainable innovation and delivering long-term value for its shareholders.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | 0.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.14 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | $27.47M |
| % Insiders | 0.00% |
| % Institutions | 64.12% |
Volatility is currently expanding